Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LAUREL
- Sponsors Roche
- 07 Nov 2017 Planned End Date changed from 31 Mar 2019 to 20 Aug 2020.
- 07 Nov 2017 Planned primary completion date changed from 31 Mar 2019 to 20 Aug 2020.
- 04 May 2016 Planned End Date changed from 1 Oct 2019 to 1 Mar 2019.